The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues. See why ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

On Tuesday, 11 March 2025, Catalyst Pharmaceuticals (NASDAQ: CPRX) presented at the Barclays 27th Annual Global Healthcare Conference. The company highlighted its strategic focus on organic growth ...

Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $24.64. The firm has a market cap of $2.51 billion, a P/E ratio of 17.52, a P/E/G ratio of 3.31 and a beta of 0.84 ...

In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, ...

Leaders turn to skills-based talent strategies to navigate uncertainty and boost productivity in the age of AI.

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...